Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, February 16, 2018
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer
Monday, February 12, 2018
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet
Thursday, February 1, 2018
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan
Monday, January 22, 2018
Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib)
Saturday, January 20, 2018
Eisai: Drug Approval of Bile Acid Transporter Inhibitor "GOOFICE 5mg" Tablet Obtained in Japan
Friday, January 19, 2018
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan
Eisai Enters into Licensing Agreement with Adlai Nortye for Potential Anticancer Agent E7046
Thursday, January 18, 2018
Eisai: Patent Infringement Litigation for Antiemetic Agent ALOXI in the United States
Thursday, January 11, 2018
Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China
Tuesday, January 9, 2018
Biogen and Eisai Commence Co-Promotion of Multiple Sclerosis Treatments in Japan

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: